title: Human leucocyte antigen-Bw4 and Gag-specific T cell responses are associated with slow disease progression in HIV-1B-infected anti-retroviral therapy-naive Chinese.
abstract: In China, the majority of human immunodeficiency virus (HIV) infections are predominately subtype B. It is important to characterize the HIV-1 subtype B-specific and its T cell response within the Chinese population, with the aim of identifying protective correlates of immunity to control HIV-1 infections. In this study, we performed a comprehensive analysis looking into the magnitude/strength of T cell responses directed at the Gag protein of the HIV-1 subtype B, one of the most conserved HIV-1 proteins. The study group consisted of anti-retroviral native and chronic HIV-1 subtype B-infected individuals. We used enzyme-linked immunospot (ELISPOT) assay to quantify the total T cell responses to HIV-1 Gag at the single peptide level. Twenty-eight (38%) peptides were recognized in 24 (82·8%) individuals. The p24 was identified as the most frequently recognized subunit protein with the greatest T cell response in the test, which correlated positively with CD4(+)  T cell count and inversely with viral load (VL). At the level of the human leucocyte antigen (HLA) supertypes, we detected the highest levels and a significant correlation with both the CD4(+)  T cell count and the VL with Gag T cell responses in Bw4/Bw4. These findings demonstrate that (i) the HIV-1B Gag p24-specific immune responses play an important role in controlling viral replication and slowing clinical progression; and (ii) HLA-Bw4/Bw4 allele has stronger T cell responses, which is associated with slow clinical progression in Chinese HIV patients.
authors: YouAn Hospital, Capital Medical University, Beijing, China.
authors: W-H
authors: WH
authors: Li
authors: C-Y
authors: CY
authors: Li
authors: H-B
authors: HB
authors: Yang
authors: H-P
authors: HP
authors: Zhang
authors: X
authors: X
authors: Zhang
authors: L-S
authors: LS
authors: Kong
authors: X-N
authors: XN
authors: Xu
authors: S-C
authors: SC
authors: Lu
authors: H-P
authors: HP
authors: Yan
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D018450:Disease Progression; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology / Q000821:virology*; D015497:HIV-1 / Q000145:classification / Q000276:immunology*; D015235:HLA-B Antigens / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D013601:T-Lymphocytes / Q000276:immunology*; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000276:immunology*
chemical_list: D015235:HLA-B Antigens; C042388:HLA-Bw4 antigen; D054301:gag Gene Products, Human Immunodeficiency Virus
references: J Virol. 2003 Feb;77(3):2081-92
references: 12525643
references: J Virol. 2011 Apr;85(7):3507-16
references: 21270166
references: J Virol. 1994 Sep;68(9):6103-10
references: 8057491
references: AIDS. 2004 Mar 5;18(4):597-604
references: 15090764
references: J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8
references: 9266987
references: Viral Immunol. 2011 Jun;24(3):189-98
references: 21668360
references: J Virol. 2007 Oct;81(19):10209-19
references: 17634242
references: J Exp Med. 2009 Jun 8;206(6):1253-72
references: 19487423
references: PLoS One. 2011;6(8):e23735
references: 21886819
references: PLoS One. 2011;6(10):e26096
references: 22022524
references: AIDS Res Hum Retroviruses. 2002 Sep 20;18(14):1067-79
references: 12396458
references: PLoS One. 2012;7(1):e30307
references: 22276176
references: Tissue Antigens. 1998 Jul;52(1):57-66
references: 9714475
references: J Virol. 2001 Dec;75(24):11983-91
references: 11711588
references: AIDS. 2008 Jun 19;22(10):1222-4
references: 18525269
references: J Infect Dis. 2002 Oct 15;186(8):1177-80
references: 12355372
references: J Virol. 2003 Jan;77(2):882-90
references: 12502804
references: Med Sci (Paris). 2008 Dec;24(12):1030-2
references: 19116110
references: J Virol. 2008 Oct;82(19):9795-9
references: 18653457
references: J Virol. 2002 Sep;76(17):8757-68
references: 12163596
references: Nat Med. 2007 Jan;13(1):46-53
references: 17173051
references: J Virol. 2002 Dec;76(24):12603-10
references: 12438586
references: N Engl J Med. 2009 Dec 3;361(23):2209-20
references: 19843557
references: PLoS One. 2011;6(10):e25786
references: 21998698
references: Methods Mol Biol. 2003;210:143-71
references: 12412454
references: J Virol. 2006 Mar;80(6):3122-5
references: 16501126
references: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5140-5
references: 11309482
references: Nat Struct Mol Biol. 2004 Jul;11(7):672-5
references: 15208690
references: J Virol. 2005 Apr;79(8):4908-17
references: 15795276
references: Nat Rev Immunol. 2008 Aug;8(8):619-30
references: 18617886
references: Nat Protoc. 2009;4(4):461-9
references: 19282851
references: J Immunol. 2007 Mar 1;178(5):2746-54
references: 17312117
references: Blood. 2006 Jun 15;107(12):4781-9
references: 16467198
references: J Virol. 2007 Mar;81(5):2440-8
references: 17182686
references: J Infect Dis. 2001 Nov 15;184(10):1268-78
references: 11679915
references: J Virol. 2006 Apr;80(7):3617-23
references: 16537629
references: J Virol. 1999 Nov;73(11):9153-60
references: 10516022
references: PLoS One. 2011;6(8):e24244
references: 21909386
references: J Virol. 2008 Jun;82(11):5398-407
references: 18353945
references: J Virol. 2002 Mar;76(5):2298-305
references: 11836408
references: J Virol. 2001 Sep;75(18):8681-9
references: 11507213
references: J Immunol. 2005 Oct 1;175(7):4789-96
references: 16177128
references: J Acquir Immune Defic Syndr. 2006 Jul;42(3):263-8
references: 16763520
references: Nat Immunol. 2006 Feb;7(2):173-8
references: 16369537